SCHEDULE: OrbiMed Discloses 9.97% Stake in Vistagen Therapeutics

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly reported a combined beneficial ownership of 9.97% of Vistagen Therapeutics, Inc.'s common stock.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital LLC, both Delaware-organized investment advisers, have filed a Schedule 13G regarding their beneficial ownership in Vistagen Therapeutics, Inc.
• As of September 30, 2025, OrbiMed Advisors LLC beneficially owns 1,420,300 shares of Vistagen Therapeutics' common stock, representing 4.63% of the class.
• OrbiMed Capital LLC beneficially owns 1,639,700 shares, representing 5.34% of the class.
• Combined, the reporting persons hold an aggregate of 3,060,000 shares, which constitutes 9.97% of Vistagen Therapeutics, Inc.'s common stock.
• OrbiMed Advisors LLC has shared voting and dispositive power over its shares, while OrbiMed Capital LLC has sole voting and dispositive power over its shares.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by a reputable healthcare-focused institutional investor, which is generally a positive signal for the company. However, it does not provide operational or financial performance details from the issuer, thus limiting a stronger positive sentiment.

Positives

• A significant stake (9.97%) by a prominent institutional investor like OrbiMed, which specializes in healthcare, may signal confidence in Vistagen Therapeutics' long-term prospects.
• The filing indicates a passive investment, suggesting OrbiMed is not seeking to influence control, which can be viewed positively by existing management and shareholders.

Risks

• The filing itself does not detail specific risks related to Vistagen Therapeutics, Inc.'s operations or financial health. It is a disclosure of beneficial ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Vistagen Therapeutics, Inc. It solely pertains to the beneficial ownership disclosure by OrbiMed.

Management Comments

• Carl L. Gordon, a Member of both OrbiMed Advisors LLC and OrbiMed Capital LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of the issuer.

Industry Context

OrbiMed is a leading investment firm focused exclusively on the healthcare sector, including biotechnology and pharmaceuticals. Their significant stake in Vistagen Therapeutics, a clinical-stage biopharmaceutical company, aligns with their investment strategy and indicates their belief in the potential of companies within this industry.

Comparison to Industry Standards

• Institutional ownership levels vary widely across the biotechnology sector. A nearly 10% stake by a specialized healthcare investor like OrbiMed is a notable position, often seen in companies with promising pipelines or strategic value. For example, similar stakes by specialized funds are common in emerging biotech firms like those developing novel therapies, where long-term growth potential is a key driver for investment.

Stakeholder Impact

• Shareholders: Increased institutional ownership may enhance market confidence and liquidity for Vistagen Therapeutics' stock.
• Management: The passive nature of OrbiMed's investment suggests no immediate intent to influence corporate control, allowing current management to continue their strategic direction.

Key Dates

Recommendation

The Schedule 13G filing indicates a significant passive stake by OrbiMed, a prominent healthcare investor. While this signals institutional confidence, the filing itself does not contain operational or financial performance data to warrant a stronger recommendation. Investors should monitor Vistagen's future operational updates and OrbiMed's continued involvement.

Keywords

Vistagen Therapeutics, OrbiMed, Schedule 13G, beneficial ownership, common stock, institutional investor, biotechnology, pharmaceutical, investment adviser